Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its ...

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute ...

Citi downgraded Schrodinger ( NASDAQ: SDGR) to Neutral from Buy after the AI-focused biotech announced its decision to discontinue a clinical program for a leukemia candidate following the emergence ...

Schrödinger is abandoning its CDC7 inhibitor after the therapy was linked to the deaths of two patients in a phase 1 leukemia trial. The biotech had been evaluating the asset, dubbed SGR-2921, in an ...

Third Patient Treated with HG-CT-1 CAR-T Therapy and Completion of First Adult Dose Cohort LONDON, UNITED KINGDOM / ACCESS ...

Amir Fathi, MD, leukemia specialist at Massachusetts General Hospital, discusses the importance of advocacy by both patients ...

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said a third patient has been successfully treated under its phase one trial of its CAR-T cell therapy, HG-CT-1, for relapsed or refractory ...

Schrödinger (Nasdaq: SDGR) has halted the clinical development of its oral drug SGR-2921 following the occurrence of two ...

Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, ...

Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in relapsed/refractory ...

Researchers sought to determine whether elderly, fit patients with AML would respond to therapy with venetoclax plus modified intensive chemotherapy.

Schrodinger discontinued its study of a potential treatment for acute myeloid leukemia or high-risk myelodysplastic syndromes, citing patient deaths linked to the treatment.